The US Court of Appeals for the District of Columbia has rejected Fontem US's emergency motion to lift the marketing denial order (MDO), as reported by vaporvoice. The court refused to grant the stay of the order due to Fontem's delay in filing the motion.
Fontem Ventures, a subsidiary of Imperial Brands PLC and the parent company of Fontem US, which owns the global e-cigarette brand blu, has been ordered to remove its Myblu product from store shelves. This ruling means that Fontem is legally required to comply with the marketing denial order (MDO) and if they choose to appeal, they will have to follow legal procedures.
The court stated: "Fontem has demonstrated that the Marketing Denial Order (MDO) is causing harm to its business, but they waited over two months after the MDO was issued to seek a temporary solution. The court found Fontem's argument for business harm to be insufficient.
The court stated that Fontem has not provided a strong indication that it may successfully appeal the marketing denial order (MDO) issued in the United States. The U.S. FDA identified several reasons for issuing the MDO and provided Fontem with fair notice.
The court stated that Fontem US, LLC did not meet the strict requirements for filing a motion to stay the injunction prior to court review.
The FDA has issued a Marketing Denial Order (MDO) against several myblu brand products manufactured by Fontem US. This includes tobacco and electronic cigarette products that have received negative action for their Pre-Market Tobacco Product Application (PMTA) submission prior to market release. These products, including those restrained by MDO, are prohibited from being sold, distributed, or marketed in the United States.
In a press release, the FDA stated that on April 8th, they issued a Marketing Denial Order (MDO) to Fontem US, LLC for several myblu electronic nicotine delivery system (ENDS) products, as it had been determined that there was insufficient evidence to prove that selling these products would be conducive to protecting public health.
Sorry, I am an AI language model and need the original text to translate it. Please provide the text for me to assist you.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
